Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-04-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
2024年度独立董事履职报告(秦拯)
Governance Information Classification · 95% confidence The document is titled as the "2024年度独立董事履职报告（秦拯）" which translates to "2024 Annual Independent Director's Performance Report (Qin Zheng)". It is a detailed report by an independent director about his duties, attendance, committee participation, communication with auditors, and governance activities during the year 2024. The content focuses on the independent director's role, oversight, and governance rather than financial results or audit opinions. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is also not a regulatory filing or announcement but a formal report on the independent director's performance and governance activities. This fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (4510 characters) and detailed content support this classification with high confidence.
2025-04-28 Chinese
2024年度独立董事履职报告(黄纯安)
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事履职报告（黄纯安）" which translates to "2024 Annual Independent Director's Performance Report (Huang Chunan)". It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and oversight activities during the year 2024. The content focuses on governance, compliance with laws and regulations, and the director's evaluation of company operations and internal controls. It is a detailed report on the independent director's annual performance and governance role rather than a general annual report or financial statement. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance reporting. The document length is 4186 characters, which is relatively short but contains substantive content about the director's role and activities, not just an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2025-04-28 Chinese
益丰药房2024年度募集资金存放与使用情况鉴证报告
Regulatory Filings
2025-04-28 Chinese
益丰药房关于续聘2025年会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the accounting firm Tianjian Certified Public Accountants for the 2025 fiscal year. It details the firm's qualifications, independence, audit fees, and the approval process by the audit committee and board of directors. There is no actual audit report or financial statements included, only information about the appointment and related procedures. The document length is 3269 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates to audit firm appointment and audit-related information but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the auditor and audit-related information, AR is the most appropriate category rather than Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2025
2025-04-28 Chinese
2024年内部控制自我评价报告
Regulatory Filings Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024 by 益丰大药房连锁股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, scope of evaluation, standards for defect recognition, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain comprehensive financial statements or detailed financial analysis. It is also not an Audit Report (AR) in the traditional sense of an external auditor's opinion on financial statements, but rather an internal control evaluation report. Given the nature of the document, it fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about internal control evaluation and does not fit other specific categories. The document length is under 5,000 characters, but it contains substantive content, so it is not a mere announcement (RPA). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-04-28 Chinese
2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Tianjian CPA Firm for the year 2024, specifically regarding their audit work for Yifeng Pharmacy Chain Co., Ltd. It details the qualifications, independence, quality management, work plan, resource allocation, information security, and risk capacity of the audit firm. The document is a standalone audit-related report focusing on the audit firm's performance and compliance with regulatory standards, rather than the full annual report or financial statements of the company. It does not contain the company's financial results or management discussion but is an audit report or information related to the audit process and quality. The document length is 2882 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-04-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.